# Nuclide record paper-cabinet-cabozantinib-nejm-2024 (paper). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/key-papers/paper-cabinet-cabozantinib-nejm-2024/>
  a schema:ScholarlyArticle ;
  nuclide:kind "paper" ;
  schema:identifier "paper-cabinet-cabozantinib-nejm-2024" ;
  schema:name "CABINET (Alliance A021602): cabozantinib for advanced neuroendocrine tumours"@en ;
  schema:description "Cabozantinib delayed progression in previously treated advanced neuroendocrine tumours of both pancreatic and extra-pancreatic origin compared with placebo, adding a new option after somatostatin analogues, everolimus or radioligand therapy."@en ;
  schema:url <https://nuclide.cc/key-papers/paper-cabinet-cabozantinib-nejm-2024/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2403991>, <https://pubmed.ncbi.nlm.nih.gov/39282913/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2403991> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "Chan JA, Geyer S, Zemla T, et al." ;
  nuclide:indications <https://nuclide.cc/indications/lung-net/>, <https://nuclide.cc/indications/pancreatic-net/>, <https://nuclide.cc/indications/small-intestinal-net/> ;
  nuclide:drugs <https://nuclide.cc/drugs/cabozantinib/> ;
  nuclide:trials <https://nuclide.cc/trials/cabinet/> ;
  nuclide:journals <https://nuclide.cc/journals/nejm/> .